| Study | Type of data | Exposure measurement | Outcome assessment | Adjustment |
|---|---|---|---|---|
| Bérard, 2018 | nested case control | The Quebec Prescription Drug Insurance database (drug name, start date, dosage, duration). | The medical service database (RAMQ: diagnoses, medical procedures, socio- economic status of women), the Hospital Records database (MedEcho: diagnoses and procedures, gestational age) and the Quebec Statistics database (ISQ: patient sociodemographic, birth weight). | Potential confounders considered: (1) socioeconomic variables; (2) maternal chronic comorbidities (diabetes, epilepsy,... ); (3) healthcare utilisation; (4) at least one diagnosis of autoimmune diseases (multiple sclerosis, …) in the year before; (5) pregnancy-related variables and other medications used during pregnancy (cholestyramine exposure during pregnancy stratified on trimester of use). |
| Chambers (Unexposed control, disease free), 2010 | prospective cohort | Each woman completed 2 or 3 structured telephone interviews during pregnancy that included exposures. Each woman was provided with a diary in which she kept a record of any additional exposures that might occur before delivery. Medical records were examined for additional exposure data. | Birth outcome was recorded on a standard form completed via telephone interview of the mother. Medical records were examined and infant’s physician also asked to return a form reporting growth measures and any major structural defect. Liveborn infants were also examined by a dysmorphologist. | None |
| Chambers (Unexposed control, sick), 2010 | prospective cohort | Each woman completed 2 or 3 structured telephone interviews during pregnancy that included exposures. Each woman was provided with a diary in which she kept a record of any additional exposures that might occur before delivery. Medical records were examined for additional exposure data. | Birth outcome was recorded on a standard form completed via telephone interview of the mother. Medical records were examined and infant’s physician also asked to return a form reporting growth measures and any major structural defect. Liveborn infants were also examined by a dysmorphologist. | Disease matched control group. |
| Karadag, 2013 | retrospective cohort | Hospital files were used for selecting patients who used leflunomide before or during pregnancy. | Hospital files. | None |
| Langen, 2014 | retrospective cohort | Data were collected from review of medical records and included medication use. | Data were collected from review of medical records and included pregnancy outcomes. | None |
| Viktil (Controls exposed to other treatments), 2012 | population based cohort propective | Prescriptions were recorded from 3 months prior to conception until labour from the Norwegian Prescription Database (NorPD). | The Medical Birth Registry of Norway (MBRN), a population based register that contains information about all births, including late abortion, from 12 weeks of gestation onwards. | None for this group of exposure. Singletons only. |
| Viktil (Controls unexposed, NOS), 2012 | population based cohort propective | Prescriptions were recorded from 3 months prior to conception until labour from the Norwegian Prescription Database (NorPD). | The Medical Birth Registry of Norway (MBRN), a population based register that contains information about all births, including late abortion, from 12 weeks of gestation onwards. | None for this group of exposure. Singletons only. |